Scientists discover antibodies that target holes in HIV's defenses

September 12, 2016, The Scripps Research Institute
The Scripps Research Institute's Dennis Burton, Gabriel Ozorowski and Andrew Ward (left to right) are among the authors of the new paper. Credit: The Scripps Research Institute.

A new study from scientists at The Scripps Research Institute (TSRI) shows that "holes" in HIV's defensive sugar shield could be important in designing an HIV vaccine.

It appears that antibodies can target these holes, which are scattered in HIV's protective sugar or "glycan" shield, and the question is now whether these holes can be exploited to induce protective antibodies.

"It's important now to evaluate future vaccine candidates to more rapidly understand the immune response they induce to particular glycan holes and learn from it," said TSRI Professor Dennis R. Burton, who is also scientific director of the International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and of the National Institutes of Health's Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) at TSRI.

The study, published recently in the journal Cell Reports, was co-led by Burton, TSRI Associate Professor Andrew Ward, also of CHAVI-ID, and Rogier W. Sanders of the University of Amsterdam and Cornell University.

A Clue to Stopping HIV

Every virus has a signature structure, like the architecture of a building. By solving these structures, scientists can put together a blueprint showing where HIV is vulnerable to infection-blocking antibodies.

In the 1990s, scientists discovered that HIV can have random holes in its protective outer shell of glycan molecules. Until now, however, scientists weren't sure if antibodies could recognize and target these holes.

Researchers at Cornell and TSRI had previously designed a stabilized version of an important HIV protein, called the envelope glycoprotein (Env) trimer, to prompt rabbit models to produce antibodies against the virus. In the new study, the plan was to reveal HIV's vulnerabilities by examining where the antibodies bound the virus.

"From work on HIV-positive individuals, we knew that the best way to understand an antibody response is to isolate the individual antibodies and study them in detail," said Laura McCoy, a TSRI, IAVI and CHAVI-ID researcher now at University College London, who served as co-first author of the study with TSRI Senior Research Associate Gabriel Ozorowski, also of TSRI and CHAVI-ID, and Marit J. van Gils of the University of Amsterdam.

To their surprise, when the researchers examined the rabbits' antibodies, they found three rabbits had produced antibodies that targeted the same hole in Env. It appeared that antibodies could indeed target holes in the glycan shield.

"This opened up a whole new concept," said Ozorowski.

If the immune system was targeting this hole—preferring it to other vulnerable spots on Env—maybe holes would be especially important in designing vaccine candidates.

Toward Better Antibodies

By analyzing the genetic sequences of thousands of strains of HIV, the researchers found that 89 percent of strains appear to have a targetable hole in the Env. The virus has a defense mechanism though—it quickly mutates to fill in these gaps.

The researchers speculate that future vaccines might prompt the immune system to create antibodies to target holes. "Targeting a hole could help the immune system get its foot in the door," Ozorowski said. Alternatively, the holes may prove a distraction and should be filled in so the immune system can focus on targeting better sites for neutralizing the virus.

Burton said researchers must investigate the different possibilities, but he emphasized that this new understanding of glycan holes could help researchers narrow down the field of molecules needed in potential HIV vaccines.

Ward added that this same method of "rational" vaccine design—where researchers use a virus's precise molecular details to prompt the to produce specific —can also be applied to efforts to fight other viruses, such as influenza and Ebola viruses.

Explore further: Scientists find surprising trait in anti-HIV antibodies

More information: Laura E. McCoy et al, Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies, Cell Reports (2016). DOI: 10.1016/j.celrep.2016.07.074

Related Stories

Scientists find surprising trait in anti-HIV antibodies

November 17, 2015
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.

New TSRI study shows HIV structure in unprecedented detail

March 3, 2016
A new study from scientists at The Scripps Research Institute (TSRI) describes the high-resolution structure of the HIV protein responsible for recognition and infection of host cells.

In pursuit of HIV vaccine, scientists shed light on antibody origins

December 15, 2015
From Peter Parker's fateful spider bite to Arthur pulling the sword from the stone at the beginning of his reign—everyone likes to know a hero's origin story.

Scientists show AIDS vaccine could work against changeable site on HIV

May 14, 2014
A vaccine or other therapy directed at a single site on a surface protein of HIV could in principle neutralize nearly all strains of the virus—thanks to the diversity of targets the site presents to the human immune system.

Researchers harness antibody evolution on the path to an AIDS vaccine

September 8, 2016
A series of new studies led by scientists at The Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI) describe a potential vaccination strategy to jump-start the selection and evolution of ...

Scientists identify immunological profiles of people who make powerful HIV antibodies

July 29, 2016
One of the main mysteries confounding development of an HIV vaccine is why some people infected with the virus make the desired antibodies after several years, but a vaccine can't seem to induce the same response.

Recommended for you

FRESH program combines basic science with social benefits for women at risk of HIV

September 14, 2018
A program established by investigators from the Ragon Institute of Massachusetts General Hospital (MGH), MIT and Harvard is addressing the persistently elevated risk of HIV infection among young women in South Africa from ...

New study finds HIV outbreak in Indiana could have been prevented

September 13, 2018
An HIV outbreak among people who inject drugs in Indiana from 2011 to 2015 could have been avoided if the state's top health and elected officials had acted sooner on warnings, a new study by the Yale School of Public Health ...

Largest study of 'post-treatment controllers' reveals clues about HIV remission

September 13, 2018
Most HIV patients need to take daily anti-retroviral therapy—if they suspend treatment, HIV will rebound within 3-4 weeks. But clinical trials have revealed that a small fraction of patients can stop taking medications ...

Very few sexually active gay and bisexual men use prophylactic drug to prevent HIV transmission, study finds

September 12, 2018
Only 4 percent of sexually active gay and bisexual men in the United States use Truvada, a highly effective medication used to prevent the transmission of HIV, according to the results of a first-of-its-kind study.

Special antibodies could lead to HIV vaccine

September 10, 2018
Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against HIV. Researchers from the ...

Researchers date 'hibernating' HIV strains

September 5, 2018
Researchers at the BC Centre for Excellence in HIV/AIDS (BC-CfE) and Simon Fraser University (SFU), in partnership with University of British Columbia (UBC) and Western University, have developed a novel way for dating "hibernating" ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.